Physician profile
Keyur Patel
NPI 1326340555
$1,125.88
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what 84% of Undersea and Hyperbaric Medicine (Emergency Medicine) providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $24.67 · 2021: $22.78 · 2022: $187 · 2023: $83.24 · 2024: $107 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $285.99 | 2019-2025 | Renasys Touch, Collagenase Santyl, Grafix Pl |
| Genzyme Corporation | $137.00 | 2022 | |
| Intuitive Surgical, INC. | $135.00 | 2025 | |
| Tactile Systems Technology INC | $118.39 | 2019 | |
| Paratek Pharmaceuticals, INC. | $83.42 | 2019-2024 | Nuzyra |
| Hartmann USA, INC. | $52.58 | 2025 | Zetuvit Plus 10x10 P10 |
| Molnlycke Health Care US, LLC | $46.38 | 2025 | Mepilex Border Flex, Mepilex, Exufiber |
| Otsuka America Pharmaceutical, INC. | $39.50 | 2025 | Rexulti |
| Ucb, INC. | $33.41 | 2024 | Nayzilam |
| Osiris Therapeutics INC. | $31.22 | 2019 | |
| Sobi, INC | $24.67 | 2020 | |
| Kerecis Limited | $23.96 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Misonix INC | $22.78 | 2021 | |
| Organogenesis INC. | $22.71 | 2023 | Puraply |
| Octapharma USA, INC. | $22.19 | 2023 | Cutaquig |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Next Science LLC | $17.47 | 2019 | |
| Mimedx Group, INC. | $14.94 | 2025 | |
| Cashflow Solutions, LLC | $14.27 | 2024 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keyur Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.